Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
AnteoTech Ltd ( (AU:ADO) ) has shared an update.
AnteoTech has secured a US$185,000 AnteoBind order from the Serum Institute of India under its five-year supply agreement, with shipment set for early January 2026, while simultaneously deepening the relationship through SII’s evaluation of a new AnteoBind-activated ELISA plate prototype targeting a market that accounts for roughly 40% of the global immunoassay segment. The company reports growing momentum in its Life Sciences business, including approximately AU$70,000 in new sales to Japanese customers, a sharp increase in AnteoBind NXT evaluations across major global markets, re-engagement with large life sciences players on joint CLIA and ELISA product development, and a strategic shift from additive supplier to core-ingredient provider, supported by recent peer-reviewed publications and expanded commercial activity in India, positioning AnteoTech to tap into the sizeable and fast-growing CLIA and ELISA markets in 2026 and beyond.
The most recent analyst rating on (AU:ADO) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on AnteoTech Ltd stock, see the AU:ADO Stock Forecast page.
More about AnteoTech Ltd
AnteoTech Ltd is an Australian life sciences company focused on advanced surface chemistry solutions for immunoassay and diagnostic applications. Its core AnteoBind technology is used to improve performance, ease of use and cost efficiency in assays such as ELISA and chemiluminescent immunoassays (CLIA), with a growing market focus across Europe, North America, Asia and particularly the expanding Indian biotechnology sector.
Average Trading Volume: 1,321,314
Technical Sentiment Signal: Hold
Current Market Cap: A$46.37M
Find detailed analytics on ADO stock on TipRanks’ Stock Analysis page.